SCHEMBL4373510

SCHEMBL4373510

C=C(C)C(=O)c1cc(C(=O)O)cc(C(=O)N(C)CCC)c1.C=C(C)C(=O)c1cc(C(=O)OC)cc(C(=O)N(C)CCC)c1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.36
KDM4E B2RXH2 6/20 0.35
ALDH1A1 P00352 5/20 0.34
SLC7A5 Q01650 1/20 0.34
ACACB O00763 2/20 0.33
HSD17B10 Q99714 1/20 0.33
HCAR3 P49019 1/20 0.33
MAPT P10636 2/20 0.33
PLA2G2A P14555 1/20 0.33
CA12 O43570 1/20 0.33
CA1 P00915 1/20 0.33
CA2 P00918 1/20 0.33
CA7 P43166 1/20 0.33
CA9 Q16790 1/20 0.33
CA14 Q9ULX7 1/20 0.33
MEN1 O00255 1/20 0.32
KMT2A Q03164 1/20 0.32
NAMPT P43490 1/20 0.32
KDM6B O15054 1/20 0.32
KDM5C P41229 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3857901 0.95 LMNA (0.40) LMNAKDM4EALDH1A1SLC7A5ACACB
SCHEMBL3854193 0.91 HCAR3 (0.37) ALDH1A1ACACBHCAR3MAPTPLA2G2A
SCHEMBL27531885 0.83 KDM4E (0.46) LMNAKDM4EALDH1A1SLC7A5HSD17B10
SCHEMBL3886309 0.82 LMNA (0.43) LMNAKDM4EALDH1A1SLC7A5ACACB
SCHEMBL5155253 0.81 PLA2G2A (0.47) LMNAKDM4EMAPTPLA2G2AKMT2A
SCHEMBL5156755 0.81 MEN1 (0.39) LMNAKDM4EALDH1A1HSD17B10HCAR3
SCHEMBL3854271 0.80 HCAR3 (0.44) ALDH1A1ACACBHCAR3PLA2G2ACA12
SCHEMBL5158669 0.80 LMNA (0.39) LMNAKDM4EALDH1A1ACACBHSD17B10
SCHEMBL5156377 0.79 NOTUM (0.37) LMNAKDM4EALDH1A1HSD17B10MAPT
SCHEMBL3854874 0.79 NOTUM (0.48) LMNAKDM4EALDH1A1ACACBHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7618978-B2 Amides as BACE inhibitors ELI LILLY AND COMPANY (US) 2009-11-17 US disclosed
US-20070225372-A1 Amides as Bace Inhibitors ELI LILLY AND COMPANY 2007-09-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070225372-A1 Amides as Bace Inhibitors BACE2, BACE1, APP LMNA 1677/4885KDM4E 453/4885ALDH1A1 661/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.